BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Effects of soy supplementation on gene expression in breast cancer

Dataset: Effects of soy supplementation on gene expression in breast cancer

Background There are conflicting reports on the impact of soy on breast carcinogenesis. This study examines the effects of soy...

Registered by ArrayExpress Uploader
View Dataset

Background There are conflicting reports on the impact of soy on breast carcinogenesis. This study examines the effects of soy supplementation on breast cancer-related genes and pathways. Methods Women (n = 140) with early-stage breast cancer were randomized to soy protein supplementation (n = 70) or placebo (n = 70) for 7 to 30 days, from diagnosis until surgery. Adherence was determined by plasma isoflavones: genistein and daidzein. Gene expression changes were evaluated by NanoString inin pre- and post-treatment tumor tissue. Genome-wide expression analysis was performed on post-treatment tissue. Proliferation (Ki67) and apoptosis (Cas3) were assessed by immunohistochemistry. Results Plasma isoflavones rose in the soy group (two-sided Wilcoxon rank-sum test, P < .001) and did not change in the placebo group. In paired analysis of pre- and post-treatment samples, 21 genes (out of 202) showed altered expression (two-sided Student’s t-test, P < .05). Several genes including FANCC and UGT2A1 revealed different magnitude and direction of expression changes between the two groups (two-sided Student’s t-test, P < .05). A high-genistein signature consisting of 126 differentially expressed genes was identified from microarray analysis of tumors. This signature was characterized by overexpression (>2 fold) of cell cycle transcripts, including those which promote cell proliferation, such as FGFR2, E2F5, BUB1, CCNB2, MYBL2, CDK1, and CDC20 (P < .01). Soy intake did not result in statistically significant changes in Ki67 or Cas3. Conclusions Gene expression associated with soy intake and high plasma genistein define a signature characterized by overexpression of FGFR2 and genes that drive cell cycle and proliferation pathways. These findings raise the concerns that in a subset of women soy could adversely affect gene expression in breast cancer. Genome-wide expression analysis was performed on breast cancer tissue from women following treatment with soy (n=28) or placebo (n=23).

Species:
human

Samples:
51

Source:
E-GEOD-58792

Updated:
Dec.12, 2014

Registered:
Jul.10, 2014


Factors: (via ArrayExpress)
Sample MENOPAUSAL STATUS TREATMENT PLASMA GENISTEIN NG/ML ER.STATUS PREDICTED MOLECULAR SUBTYPE
GSM1419673 pre placebo 1.5 P LumA
GSM1419672 post placebo 0 N LumB
GSM141967 pre soy 46.9 P LumB
GSM1419670 pre soy 5.9 P LumA
GSM1419669 post soy 169 P LumA
GSM1419668 pre soy 155 N basal
GSM1419667 pre soy 38.3 P LumA
GSM1419666 pre soy 4.8 P LumA
GSM1419665 post placebo 2.1 P LumA
GSM1419664 pre placebo 3.6 P LumA
GSM1419663 post soy 9.7 P LumA
GSM1419662 pre soy 3.76 P LumA
GSM141966 pre placebo 0.33 P LumA
GSM1419660 post placebo 0.36 P LumB
GSM1419659 pre soy 0.61 P LumB
GSM1419658 pre placebo 0.36 N basal
GSM1419657 post placebo 0.34 P LumA
GSM1419656 pre soy 0.35 P LumA
GSM1419655 pre soy 0.34 P LumA
GSM1419654 pre placebo 0.35 P LumA
GSM1419653 post placebo 0.53 P LumA
GSM1419652 post soy 0.34 P LumB
GSM141965 pre soy 1.4 P LumA
GSM1419650 pre soy 27 P LumB
GSM1419649 pre soy 84.5 N basal
GSM1419648 pre placebo 0.33 N basal
GSM1419647 post soy 0.34 N basal
GSM1419646 post soy 110 P LumB
GSM1419645 pre soy 0.34 N Her2
GSM1419644 pre soy 0.33 N basal
GSM1419643 pre soy 9.62 P LumB
GSM1419642 post placebo 1.64 P LumB
GSM141964 post placebo 4.5 P LumA
GSM1419640 post placebo 1.45 P LumA
GSM1419639 post soy 1.12 N basal
GSM1419638 post placebo 1.86 P LumA
GSM1419637 post soy 37.01 N Her2
GSM1419636 pre placebo 1.25 P LumA
GSM1419635 post soy 93.3 P LumB
GSM1419634 post soy 1.93 P LumA
GSM1419633 post soy 201.02 P LumB
GSM1419632 post placebo 2.47 P LumA
GSM141963 pre placebo 6.89 P LumA
GSM1419630 post soy 387.86 N basal
GSM1419629 post placebo 6.45 P LumA
GSM1419628 post placebo 3.31 P LumB
GSM1419627 post placebo 1.32 P LumB
GSM1419626 post soy 1.15 N basal
GSM1419625 pre placebo 1.29 P LumA
GSM1419624 post soy 51.61 P LumB
GSM1419623 pre soy 6.26 P LumB

Tags

  • breast
  • breast cancer
  • cancer
  • cell
  • genome
  • protein

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2026 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use